Patent classifications
C12N2500/40
Method of Preparing Cancer Spheroid and Method of Selecting Colorectal Cancer Patient
The disclosure includes a method of preparing a cancer spheroid, a method of selecting a colorectal cancer patient being sensitive to an FGFR inhibitor, and a pharmaceutical composition for treating colorectal cancer comprising an FGFR inhibitor.
Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord
The present invention relates to a method of isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population isolated from the amniotic membrane of the umbilical cord, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH ADENOSINE A2A RECEPTOR ANTAGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND ADENOSINE A2A RECEPTOR ANTAGONISTS
Methods of expanding tumor infiltrating lymphocytes (TILs) in the presence of an adenosine A2A receptor (A2aR) antagonist, such as vipadenant, CPI-444 (ciforadenant), SCH58261, SYN115, ZM241385, SCH420814, a xanthine superfamily A2aR antagonist, or related adenosine receptor 2A antagonist, and uses of expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, therapeutic combinations of TILs and A2aR antagonists, including compositions and uses thereof in the treatment of diseases such as cancer are disclosed herein.
MESENCHYMAL STEM CELL STORING OR TRANSPORT FORMULATION AND METHODS OF MAKING AND USING THE SAME
The present invention relates to a mesenchymal stem cell storing or transport formulation, a method of preparing the mesenchymal stem cell toring or transport formulation as well as to methods of using the mesenchymal stem cell storing or transport formulation. Such methods include a method of transporting mesenchymal stem cells in this storing or transport formulation as well as a method of treating a subject having a disease, the method comprising topically administering mesenchymal stem cells that have been stored or transported in this storing or transport formulation. Also concerned is a unit dosage of the mesenchymal stem cells.
FORMULA OF SERUM-FREE MEDIUM FOR HUMAN PLURIPOTENT STEM CELLS
The present invention discloses formulation of a serum-free medium used for human pluripotent stem cells, which comprises the following raw materials: inorganic salt components, organic components, amino acids and amino acid salts, energy substances and metabolic intermediates, vitamins and antioxidants, proteins and polypeptides, trace elements and chromogenic substances; while the culture process comprises the following steps: selecting a basic formulation, performing combination screening, identifying and evaluating results, and testing a new formulation of culture; and proportioning according to the following methods: adding aforesaid raw materials into 950 ml of water for injection, stirring gently until dissolved, and finally adding 2.438 g of sodium bicarbonate, and stirring gently until dissolved, and then adding 1 liter of water for injection, adjusting the pH to the desired value with 1 mol/L sodium hydroxide solution or 1 mol/L hydrochloric acid solution, finally filtering sterilized with 0.1 m diameter filter under positive pressure, and storing the medium solution in dark place at 2 C.-8 C., the invention solves the problem of high cost of domestic import of serum-free formulation.
IMMUNE CELL ACTIVATION
The invention refers to a method for preparing novel and powerful regulatory B cells (Breg-nov) by contacting cells obtained from the immune system with phosphorothioate oligonucleotide. Methods of suppressing-autoimmunity or suppressing acute or chronic inflammation or repairing a damaged organ or tissue in mammals, including humans, by administering to the mammals in need, Breg-nov cells obtained as herein described.
Cell Culture Medium for Eukaryotic Cells
Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.
Cell culture medium for eukaryotic cells
Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.
CULTURE SYSTEM FOR CHEMICALLY INDUCING GENERATION OF PLURIPOTENT STEM CELLS AND CHEMICAL REPROGRAMMING METHOD USING SAME
Disclosed herein is a culture system for chemical induction of pluripotent stem cells, comprising a basic culture medium and a composition for performing chemical induction of reprogramming process. The said composition comprises a thymine analogue, a cAMP activator, a TGF- receptor inhibitor, a bone morphogenetic protein, a RA receptor activator, a GSK3 inhibitor and a basic fibroblast growth factor. And the said culture system is free of serum. By using the culture system as described herein, there is no need to frequently replate cells during culture, such that culturing process is simplified and loss of cells resulting from replating cells is reduced. As the culture system is free of serum, subsequent collection of pluripotent stem cells and molecular mechanism analysis are simplified, thereby facilitating establishment of no animal origin culture systems for induction of pluripotent stem cells.
METHOD OF INDUCING DEDIFFERENTIATION OF SOMATIC CELLS WITH SMALL MOLECULES TO PREPARE REJUVENATED MESENCHYMAL STEM CELLS AND USES THEREOF
A preparation method and applications of rejuvenated and regenerative fibroblasts, where the rejuvenated and regenerative fibroblasts are prepared from normal fibroblasts by inhibiting the JAK-STAT signaling pathway. The rejuvenated and regenerative fibroblasts are prepared by treating the target cells with a small molecular combination, a cytokine combination or a recombinant protein combination. This application further provides an application of the rejuvenated and regenerative fibroblasts in the reprogramming or rejuvenation of cells, tissues, organs and organisms.